- Home
- MGNX vs YTRA Comparison
MGNX vs YTRA Comparison
Compare MGNX & YTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- YTRA
- Stock Information
- Founded
- MGNX 2000
- YTRA 2005
- Country
- MGNX United States
- YTRA India
- Employees
- MGNX N/A
- YTRA N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- YTRA Transportation Services
- Sector
- MGNX Health Care
- YTRA Consumer Discretionary
- Exchange
- MGNX Nasdaq
- YTRA Nasdaq
- Market Cap
- MGNX 99.7M
- YTRA 106.2M
- IPO Year
- MGNX 2013
- YTRA N/A
- Fundamental
- Price
- MGNX $1.50
- YTRA $1.60
- Analyst Decision
- MGNX Hold
- YTRA Strong Buy
- Analyst Count
- MGNX 6
- YTRA 1
- Target Price
- MGNX $3.20
- YTRA $3.00
- AVG Volume (30 Days)
- MGNX 828.6K
- YTRA 143.4K
- Earning Date
- MGNX 11-04-2025
- YTRA 11-12-2025
- Dividend Yield
- MGNX N/A
- YTRA N/A
- EPS Growth
- MGNX N/A
- YTRA N/A
- EPS
- MGNX N/A
- YTRA 0.01
- Revenue
- MGNX $165,495,000.00
- YTRA $114,229,876.00
- Revenue This Year
- MGNX N/A
- YTRA N/A
- Revenue Next Year
- MGNX N/A
- YTRA N/A
- P/E Ratio
- MGNX N/A
- YTRA $253.29
- Revenue Growth
- MGNX 303.47
- YTRA 82.82
- 52 Week Low
- MGNX $0.99
- YTRA $0.58
- 52 Week High
- MGNX $4.39
- YTRA $2.00
- Technical
- Relative Strength Index (RSI)
- MGNX 43.25
- YTRA 54.89
- Support Level
- MGNX $1.30
- YTRA $1.34
- Resistance Level
- MGNX $1.69
- YTRA $1.55
- Average True Range (ATR)
- MGNX 0.11
- YTRA 0.10
- MACD
- MGNX -0.02
- YTRA 0.01
- Stochastic Oscillator
- MGNX 31.01
- YTRA 51.92
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
About YTRA Yatra Online Inc.
Yatra Online Inc is an Indian consumer travel platform provider and online travel agent. The company is organized into the following business segments; Air Ticketing which derives maximum revenue, Hotels and Packages, and Other Services. It mainly provides travel-related services, which include domestic and international air ticketing, hotel bookings, homestays, holiday packages, bus ticketing, rail ticketing, activities and ancillary services. It also involves hosting advertisements on its internet websites, the sale of rail and bus tickets, and facilitating website access to travel insurance companies. Some of its applications include Yatra Mini, Yatra Web Check-In, Yatra Corporate, and Travelguru HomeStay.